Cidara Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Cidara Therapeutics Stock Forecast and Price Target
If Cidara Therapeutics's stock price reached the average yearlong target of $25.00 given by well-known analysts in recent months, there would be a potential upside of approximately 97.16% from its last closing price in May, 2024. This potential increase is based on a high estimate of $25.00 and a low estimate of $25.00. If you're interested in CDTX stock, looking at its competitors might also be a good idea.
97.16% Upside
Cidara Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Cidara Therapeutics's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $13.62, which would mean an increase of 100.00%. Over the next seven years, experts predict that Cidara Therapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$160.81 | Buy/Sell | $178.42 | 15.04% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$278.39 | Buy/Sell | $303.65 | 14.77% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.33 | Buy/Sell | $87.82 | 22.46% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$213.51 | Buy/Sell | $299.62 | 35.12% |
Cidara Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Cidara Therapeutics's Revenue has grown by 432.64%, rising from $12.07M to $64.29M. In the next year, 3 analysts estimate that Cidara Therapeutics's Revenue will decrease by 67.23%, reaching $21.07M. Over the next seven years, experts predict that Cidara Therapeutics's Revenue will grow at a rate of 57.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$83.80 | Buy/Sell | $111.56 | 31.26% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.09 | Buy/Sell | $77.05 | 47.86% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$75.76 | Buy/Sell | $34.00 | 51.80% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.00 | Buy/Sell | $85.71 | 2.80% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.88 | Buy/Sell | $20.42 | 97.98% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
Cidara Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Cidara Therapeutics's EBITDA has decreased by 58.66%, going from $-71.56M to $-29.58M. In the next year, analysts believe that EBITDA will reach $-44.82M – an increase of 51.51%. For the next eight years, the forecast is for EBITDA to grow by 65.74%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.43 | Buy/Sell | $17.90 | 91.75% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.13 | Buy/Sell | $52.00 | 127.93% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.08 | Buy/Sell | $33.78 | 75.64% |
Cidara Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Cidara Therapeutics's EBIT has decreased from $-71.85M to $-29.72M – a 58.64% drop. For the next year, analysts predict that EBIT will reach $-58.16M – an increase of 95.69%. In 2030, the professionals' prediction is that CDTX's EBIT will decrease by 288.09%, reaching $55.90M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$40.86 | Buy/Sell | $63.29 | 88.45% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.88 | Buy/Sell | $42.58 | 14.87% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.58 | Buy/Sell | $40.00 | 28.69% |
Cidara Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Cidara Therapeutics's EPS has grown by 100.00%, rising from $-1.80 to $0.00. For next year, analysts predict EPS of $-0.58, which would mean an increase of 100.00%. Over the next seven years, experts predict that Cidara Therapeutics's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.79 | Buy/Sell | $9.94 | 98.82% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.74 | Buy/Sell | $6.00 | 18.69% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.72 | Buy/Sell | $25.00 | 109.04% |
.jpg)